MicroRNA-214 reduces insulin-like growth factor-1 (IGF-1) receptor expression and downstream mTORC1 signaling in renal carcinoma cells

Journal of Biological Chemistry

Volumn 291, Issue 28, 2016, Pages 14662-14676

  Das, Falguni ^b   Dey, Nirmalya ^b   Bera, Amit ^b   Kasinath, Balakuntalam S ^a,b   Ghosh Choudhury, Nandini ^a,c   Choudhury, Goutam Ghosh ^a,b  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c University of Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROLIFERATION; CELLS; CYTOLOGY; DIAGNOSIS; DISEASES; ENZYMES; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CONSTITUTIVELY ACTIVES; INSULIN-LIKE GROWTH FACTOR-1; RECEPTOR EXPRESSION; RECIPROCAL REGULATION; RECOGNITION ELEMENT; RENAL CARCINOMA CELLS; RENAL CELL CARCINOMA; VON HIPPEL LINDAU;

CELL SIGNALING;

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; MICRORNA 214; PROTEIN KINASE B; S6 KINASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSCRIPTOME; VON HIPPEL LINDAU PROTEIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MICRORNA; MIRN214 MICRORNA, HUMAN; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

3' UNTRANSLATED REGION; ARTICLE; AUTOPHOSPHORYLATION; BETA SHEET; CARCINOMA CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN SECONDARY STRUCTURE; RNA TRANSLATION; TRANSLATION INITIATION; CELL LINE; GENETICS; KIDNEY; KIDNEY TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CARCINOMA, RENAL CELL; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MICRORNAS; MULTIPROTEIN COMPLEXES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84978976728     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.694331     Document Type: Article

References (91)

1. Karumanchi, S. A., Merchan, J., and Sukhatme, V. P. (2002) Renal cancer: molecular mechanisms and newer therapeutic options. Curr. Opin. Nephrol. Hypertens. 11, 37-42
2. Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., Kovacevic, Z., Lesovoy, V., Schmidt-Wolf, I. G., Barbarash, O., Gokmen, E., et al. (2007) Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281
3. Rouvière, O., Bouvier, R., Négrier, S., Badet, L., and Lyonnet, D. (2006) Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up? Nat. Clin. Pract. Oncol. 3, 200-213
4. McDermott, D. F., Regan, M. M., Clark, J. I., Flaherty, L. E., Weiss, G. R., Logan, T. F., Kirkwood, J. M., Gordon, M. S., Sosman, J. A., Ernstoff, M. S., Tretter, C. P., Urba, W. J., Smith, J. W., Margolin, K. A., Mier, J. W., et al. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133-141
5. Negrier, S., Escudier, B., Lasset, C., Douillard, J. Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., Philip, T., and Tursz, T. (1998) Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl. J. Med. 338, 1272-1278
6. Rosendahl, A., and Forsberg, G. (2004) Influence of IGF-IR stimulation or blockade on proliferation of human renal cell carcinoma cell lines. Int. J. Oncol. 25, 1327-1336
7. Rosendahl, A. H., Holly, J. M., Celander, M., and Forsberg, G. (2008) Systemic IGF-I administration stimulates the in vivo growth of early, but not advanced, renal cell carcinoma. Int. J. Cancer 123, 1286-1291
8. Cheung, C., Vesey, D., Cotterill, A., Douglas, M., Gobe, G., Nicol, D., and Johnson, D. (2005) Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas. Int. J. Urol. 12, 17-28
9. Rasmuson, T., Grankvist, K., Jacobsen, J., Olsson, T., and Ljungberg, B. (2004) Serum insulin-like growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma. Acta Oncol. 43, 744-748
10. Parker, A. S., Cheville, J. C., Blute, M. L., Igel, T., Lohse, C. M., and Cerhan, J. R. (2004) Pathologic T1 clear cell renal cell carcinoma: insulin-like growth factor-I receptor expression and disease-specific survival. Cancer 100, 2577-2582
11. Schips, L., Zigeuner, R., Ratschek, M., Rehak, P., Rüschoff, J., and Langner, C. (2004) Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. Am. J. Clin. Pathol. 122, 931-937
12. Parker, A. S., Cheville, J. C., Janney, C. A., and Cerhan, J. R. (2002) High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. Hum. Pathol. 33, 801-805
13. Parker, A., Cheville, J. C., Lohse, C., Cerhan, J. R., and Blute, M. L. (2003) Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J. Urol. 170, 420-424
14. Rodon, J., DeSantos, V., Ferry, R. J., Jr., and Kurzrock, R. (2008) Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol. Cancer Ther. 7, 2575-2588
15. Yakar, S., Leroith, D., and Brodt, P. (2005) The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models. Cytokine Growth Factor Rev. 16, 407-420
16. Bartel, D. P. (2009) MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233
17. Bartel, D. P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297
18. Couzin, J. (2008) MicroRNAs make big impression in disease after disease. Science 319, 1782-1784
19. Fabian, M. R., Sonenberg, N., and Filipowicz, W. (2010) Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79, 351-379
20. Grosshans, H., and Büssing, I. (2010) MicroRNA biogenesis takes another single hit from microsatellite instability. Cancer Cell 18, 295-297
21. Melo, S. A., Moutinho, C., Ropero, S., Calin, G. A., Rossi, S., Spizzo, R., Fernandez, A. F., Davalos, V., Villanueva, A., Montoya, G., Yamamoto, H., Schwartz, S., Jr., and Esteller, M. (2010) A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 18, 303-315
22. Gottardo, F., Liu, C. G., Ferracin, M., Calin, G. A., Fassan, M., Bassi, P., Sevignani, C., Byrne, D., Negrini, M., Pagano, F., Gomella, L. G., Croce, C. M., and Baffa, R. (2007) Micro-RNA profiling in kidney and bladder cancers. Urol. Oncol. 25, 387-392
23. Jung, M., Mollenkopf, H. J., Grimm, C., Wagner, I., Albrecht, M., Waller, T., Pilarsky, C., Johannsen, M., Stephan, C., Lehrach, H., Nietfeld, W., Rudel, T., Jung, K., and Kristiansen, G. (2009) MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J. Cell. Mol. Med. 13, 3918-3928
24. Das, F., Ghosh-Choudhury, N., Mahimainathan, L., Venkatesan, B., Feliers, D., Riley, D. J., Kasinath, B. S., and Choudhury, G. G. (2008) Raptorrictor axis in TGFβ-induced protein synthesis. Cell. Signal. 20, 409-423
25. Das, F., Ghosh-Choudhury, N., Dey, N., Mandal, C. C., Mahimainathan, L., Kasinath, B. S., Abboud, H. E., and Choudhury, G. G. (2012) Unrestrained mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of Akt kinase. J. Biol. Chem. 287, 3808-3822
26. Ohne, Y., Takahara, T., Hatakeyama, R., Matsuzaki, T., Noda, M., Mizushima, N., and Maeda, T. (2008) Isolation of hyperactive mutants of mammalian target of rapamycin. J. Biol. Chem. 283, 31861-31870
27. Das, F., Bera, A., Ghosh-Choudhury, N., Abboud, H. E., Kasinath, B. S., and Choudhury, G. G. (2014) TGFβ-induced deptor suppression recruits mTORC1 and not mTORC2 to enhance collagen I (α2) gene expression. PLoS ONE 9, e109608
28. Bera, A., Das, F., Ghosh-Choudhury, N., Kasinath, B. S., Abboud, H. E., and Choudhury, G. G. (2014) microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion. Exp. Cell Res. 328, 99-117
29. Dey, N., Das, F., Ghosh-Choudhury, N., Mandal, C. C., Parekh, D. J., Block, K., Kasinath, B. S., Abboud, H. E., and Choudhury, G. G. (2012) MicroRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. PLoS ONE 7, e37366
30. Bera, A., Ghosh-Choudhury, N., Dey, N., Das, F., Kasinath, B. S., Abboud, H. E., and Choudhury, G. G. (2013) NF-B-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation. Cell. Signal. 25, 2575-2586
31. Choudhury, G. G. (2001) Akt serine threonine kinase regulates plateletderived growth factor-induced DNA synthesis in glomerular mesangial cells: regulation of c-fos AND p27(kip1) gene expression. J. Biol. Chem. 276, 35636-35643
32. Venkatesan, B., Ghosh-Choudhury, N., Das, F., Mahimainathan, L., Kamat, A., Kasinath, B. S., Abboud, H. E., and Choudhury, G. G. (2008) Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B. FASEB J. 22, 3469-3482
33. Rehmsmeier, M., Steffen, P., Hochsmann, M., and Giegerich, R. (2004) Fast and effective prediction of microRNA/target duplexes. RNA 10, 1507-1517
34. Dey, N., Das, F., Mariappan, M. M., Mandal, C. C., Ghosh-Choudhury, N., Kasinath, B. S., and Choudhury, G. G. (2011) MicroRNA-21 orchestrates high glucose-induced signals to TORC1 for renal cell pathology in diabetes. J. Biol. Chem. 286, 25586-25603
35. Mandal, C. C., Ghosh-Choudhury, N., Yoneda, T., Choudhury, G. G., and Ghosh-Choudhury, N. (2011) Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J. Biol. Chem. 286, 11314-11327
36. Mahimainathan, L., Ghosh-Choudhury, N., Venkatesan, B., Das, F., Mandal, C. C., Dey, N., Habib, S. L., Kasinath, B. S., Abboud, H. E., and Ghosh Choudhury, G. (2009) TSC2 deficiency increases PTEN via HIF1α. J. Biol. Chem. 284, 27790-27798
37. Wu, C. I., Shen, Y., and Tang, T. (2009) Evolution under canalization and the dual roles of microRNAs: a hypothesis. Genome Res. 19, 734-743
38. Doench, J. G., and Sharp, P. A. (2004) Specificity of microRNA target selection in translational repression. Genes Dev. 18, 504-511
39. Bhaskar, P. T., and Hay, N. (2007) The two TORCs and Akt. Dev. Cell 12, 487-502
40. Manning, B. D., and Cantley, L. C. (2007) AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274
41. Kovacina, K. S., Park, G. Y., Bae, S. S., Guzzetta, A. W., Schaefer, E., Birnbaum, M. J., and Roth, R. A. (2003) Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J. Biol. Chem. 278, 10189-10194
42. Burgos, S. A., and Cant, J. P. (2010) IGF-1 stimulates protein synthesis by enhanced signaling through mTORC1 in bovine mammary epithelial cells. Domest. Anim. Endocrinol. 38, 211-221
43. Dey, N., Ghosh-Choudhury, N., Das, F., Li, X., Venkatesan, B., Barnes, J. L., Kasinath, B. S., and Ghosh Choudhury, G. (2010) PRAS40 acts as a nodal regulator of high glucose-induced TORC1 activation in glomerular mesangial cell hypertrophy. J. Cell. Physiol. 225, 27-41
44. Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., and Sabatini, D. M. (2007) PRAS40 is an insulinregulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25, 903-915
45. Wullschleger, S., Loewith, R., and Hall, M. N. (2006) TOR signaling in growth and metabolism. Cell 124, 471-484
46. Zoncu, R., Efeyan, A., and Sabatini, D. M. (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21-35
47. Chiang, G. G., and Abraham, R. T. (2005) Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem. 280, 25485-25490
48. Holz, M. K., and Blenis, J. (2005) Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 280, 26089-26093
49. Dowling, R. J., Topisirovic, I., Alain, T., Bidinosti, M., Fonseca, B. D., Petroulakis, E., Wang, X., Larsson, O., Selvaraj, A., Liu, Y., Kozma, S. C., Thomas, G., and Sonenberg, N. (2010) mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328, 1172-1176
50. Yi, Z., Fu, Y., Zhao, S., Zhang, X., and Ma, C. (2010) Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J. Cancer Res. Clin. Oncol. 136, 855-862
51. Kaelin, W. G., Jr. (2009) Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 115, 2262-2272
52. Young, A. P., Schlisio, S., Minamishima, Y. A., Zhang, Q., Li, L., Grisanzio, C., Signoretti, S., and Kaelin, W. G., Jr. (2008) VHL loss actuates a HIFindependent senescence programme mediated by Rb and p400. Nat. Cell Biol. 10, 361-369
53. Neal, C. S., Michael, M. Z., Rawlings, L. H., Van der Hoek, M. B., and Gleadle, J. M. (2010) The VHL-dependent regulation of microRNAs in renal cancer. BMC Med. 8, 64
54. Kaleko, M., Rutter, W. J., and Miller, A. D. (1990) Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol. Cell. Biol. 10, 464-473
55. Sell, C., Dumenil, G., Deveaud, C., Miura, M., Coppola, D., DeAngelis, T., Rubin, R., Efstratiadis, A., and Baserga, R. (1994) Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell Biol. 14, 3604-3612
56. Baserga, R. (1995) The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. 55, 249-252
57. Yakar, S., Pennisi, P., Kim, C. H., Zhao, H., Toyoshima, Y., Gavrilova, O., and LeRoith, D. (2005) Studies involving the GH-IGF axis: Lessons from IGF-I and IGF-I receptor gene targeting mouse models. J. Endocrinol. Invest. 28, 19-22
58. Almeida, A., Muleris, M., Dutrillaux, B., and Malfoy, B. (1994) The insulinlike growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer. Genes Chromosomes Cancer 11, 63-65
59. LeRoith, D., and Roberts, C. T., Jr. (2003) The insulin-like growth factor system and cancer. Cancer Lett. 195, 127-137
60. Werner, H., Karnieli, E., Rauscher, F. J., and LeRoith, D. (1996) Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. U.S.A. 93, 8318-8323
61. Werner, H., Re, G. G., Drummond, I. A., Sukhatme, V. P., Rauscher, F. J., 3rd, Sens, D. A., Garvin, A. J., LeRoith, D., and Roberts, C. T., Jr. (1993) Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc. Natl. Acad. Sci. U.S.A. 90, 5828-5832
62. Maor, S. B., Abramovitch, S., Erdos, M. R., Brody, L. C., and Werner, H. (2000) BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. Mol. Genet. Metab. 69, 130-136
63. Meng, Z., King, P. H., Nabors, L. B., Jackson, N. L., Chen, C. Y., Emanuel, P. D., and Blume, S. W. (2005) The ELAV RNA-stability factor HuR binds the 5′-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation. Nucleic Acids Res. 33, 2962-2979
64. Giraud, S., Greco, A., Brink, M., Diaz, J. J., and Delafontaine, P. (2001) Translation initiation of the insulin-like growth factor I receptormRNAis mediated by an internal ribosome entry site. J. Biol. Chem. 276, 5668-5675
65. Meng, Z., Jackson, N. L., Choi, H., King, P. H., Emanuel, P. D., and Blume, S. W. (2008) Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF-IR translational control in human breast tumor cells. J. Cell. Physiol. 217, 172-183
66. Jiang, L., Liu, X., Chen, Z., Jin, Y., Heidbreder, C. E., Kolokythas, A., Wang, A., Dai, Y., and Zhou, X. (2010) MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem. J. 432, 199-205
67. Gan, B., Lim, C., Chu, G., Hua, S., Ding, Z., Collins, M., Hu, J., Jiang, S., Fletcher-Sananikone, E., Zhuang, L., Chang, M., Zheng, H., Wang, Y. A., Kwiatkowski, D. J., Kaelin, W. G., Jr., et al. (2010) FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell 18, 472-484
68. Pichiorri, F., Suh, S. S., Rocci, A., De Luca, L., Taccioli, C., Santhanam, R., Zhou, W., Benson, D. M., Jr., Hofmainster, C., Alder, H., Garofalo, M., Di Leva, G., Volinia, S., Lin, H. J., Perrotti, D., et al. (2010) Down-regulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18, 367-381
69. Zhang, X. J., Ye, H., Zeng, C. W., He, B., Zhang, H., and Chen, Y. Q. (2010) Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J. Hematol. Oncol. 3, 46
70. Scapoli, L., Palmieri, A., Lo Muzio, L., Pezzetti, F., Rubini, C., Girardi, A., Farinella, F., Mazzotta, M., and Carinci, F. (2010) MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int. J. Immunopathol. Pharmacol. 23, 1229-1234
71. Penna, E., Orso, F., Cimino, D., Tenaglia, E., Lembo, A., Quaglino, E., Poliseno, L., Haimovic, A., Osella-Abate, S., De Pittà, C., Pinatel, E., Stadler, M. B., Provero, P., Bernengo, M. G., Osman, I., and Taverna, D. (2011) microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J. 30, 1990-2007
72. Yu, Z. W., Zhong, L. P., Ji, T., Zhang, P., Chen, W. T., and Zhang, C. P. (2010) MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral. Oncol. 46, 317-322
73. Yang, H., Kong, W., He, L., Zhao, J. J., O'Donnell, J. D., Wang, J., Wenham, R. M., Coppola, D., Kruk, P. A., Nicosia, S. V., and Cheng, J. Q. (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68, 425-433
74. Cho, D., Signoretti, S., Dabora, S., Regan, M., Seeley, A., Mariotti, M., Youmans, A., Polivy, A., Mandato, L., McDermott, D., Stanbridge, E., and Atkins, M. (2007) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 5, 379-385
75. Qian, C. N., Furge, K. A., Knol, J., Huang, D., Chen, J., Dykema, K. J., Kort, E. J., Massie, A., Khoo, S. K., Vanden Beldt, K., Resau, J. H., Anema, J., Kahnoski, R. J., Morreau, H., Camparo, P., et al. (2009) Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res. 69, 8256-8264
76. Cully, M., You, H., Levine, A. J., and Mak, T. W. (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6, 184-192
77. Cancer Genome Atlas Research Network. (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43-49
78. Abou Youssif, T., Fahmy, M. A., Koumakpayi, I. H., Ayala, F., Al Marzooqi, S., Chen, G., Tamboli, P., Squire, J., Tanguay, S., and Sircar, K. (2011) The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 117, 290-300
79. Wang, Y. H., and Huang, M. L. (2009) Reduction of Lobe leads to TORC1 hypoactivation that induces ectopic Jak/STAT signaling to impair Drosophila eye development. Mech. Dev. 126, 781-790
80. Miron, M., Verdú, J., Lachance, P. E., Birnbaum, M. J., Lasko, P. F., and Sonenberg, N. (2001) The translational inhibitor 4E-BP is an effector of PI(3)K/Akt signalling and cell growth in Drosophila. Nat. Cell Biol. 3, 596-601
81. Montagne, J., Stewart, M. J., Stocker, H., Hafen, E., Kozma, S. C., and Thomas, G. (1999) Drosophila S6 kinase: a regulator of cell size. Science 285, 2126-2129
82. De Benedetti, A., and Graff, J. R. (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23, 3189-3199
83. Graff, J. R., Konicek, B. W., Carter, J. H., and Marcusson, E. G. (2008) Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 68, 631-634
84. Hay, N., and Sonenberg, N. (2004) Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945
85. Del Bufalo, D., Ciuffreda, L., Trisciuoglio, D., Desideri, M., Cognetti, F., Zupi, G., and Milella, M. (2006) Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66, 5549-5554
86. Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S. H., Marshall, B., Boni, J. P., Dukart, G., and Sherman, M. L. (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909-918
87. Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., Urbanowitz, G., Berg, W. J., Kay, A., Lebwohl, D., and Ravaud, A. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456
88. Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., Kay, A., Ravaud, A., and RECORD-1 Study Group. (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116, 4256-4265
89. Traynor, K. (2009) New oral treatment for kidney cancer approved. Am. J. Health Syst. Pharm. 66, 788
90. Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., Gout, I., Downes, C. P., and Lamb, R. F. (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166, 213-223
91. Shah, O. J., Wang, Z., and Hunter, T. (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14, 1650-1656